Trump Administration Releases $600 Million for Global Child Vaccination After Gavi Agrees to Safety Terms

The Trump administration announced Wednesday that it would release $600 million in funding appropriated by Congress to an immunization program that serves children in poor countries. The move reverses a decision last year from Health and Human Services Secretary Robert F. Kennedy Jr. to halt U.S. funding to Geneva-based Gavi, the Vaccine Alliance, over unsubstantiated vaccine safety concerns.

The State Department said in a press release the change occurred after Gavi agreed to make “significant commitments that strengthen vaccine safety, improve public health, and better align Gavi’s work with the principles of Gold Standard Science and transparency.” The commitments include ceasing the promotion and procurement of COVID-19 vaccines for routine immunization programs and cutting down on the program’s staffing in Geneva.

The department said Gavi has also allotted the U.S. a place on its board and will allow the country to conduct oversight to ensure vaccine safety. President Trump has made clear that American leadership in global health must be rooted in accountability, scientific excellence, and measurable results, according to the State Department’s press release.

Kennedy Cites Mercury Elimination as Key Victory

Kennedy specifically cited Gavi’s commitment to eliminate “mercury-laced vaccines” from its immunization programs in a statement shared on social media. The secretary and anti-vaccine advocacy groups have linked thimerosal, a mercury-based preservative included in some vaccines, without proven evidence to incidences of autism and other neurodevelopmental disorders.

Kennedy alleged “glaringly racist policies” under the Biden administration permitted the vaccine alliance to “inject more than 72 million African and Asian children with cheap jabs containing bolus doses of the world’s most potent neurotoxin.” He wrote in a Wednesday post that under President Trump’s leadership, GAVI has agreed to eliminate mercury from the vaccines it provides to children, calling this an enormous victory for global health.

Gavi Executive Welcomes Renewed Partnership

Dr. Sania Nishtar, Gavi’s head executive, said in a Thursday statement that the program was “deeply grateful” for the U.S.’s support. This investment will help us to strengthen global defenses against outbreaks and pandemics and protect more children from preventable diseases, Nishtar explained. The United States’ partnership has been a key contributor to Gavi’s success in immunizing over 1.2 billion children since 2000, and the organization looks forward to renewing this partnership and achieving even greater impact.

The $600 million funding release marks a significant shift in U.S. policy toward global vaccination efforts, which had been frozen amid Kennedy’s concerns about vaccine safety protocols. The restoration of funding comes with enhanced oversight mechanisms that grant the United States unprecedented involvement in Gavi’s decision-making processes and operational transparency.

New Terms Reshape U.S.-Gavi Partnership

The agreement between the Trump administration and Gavi includes several structural changes to how the vaccine alliance operates. Beyond the commitment to eliminate thimerosal-containing vaccines and halt COVID-19 vaccine promotion for routine immunization, Gavi has agreed to reduce its administrative footprint in Geneva. These changes reflect the administration’s emphasis on streamlined operations and cost-effectiveness in global health initiatives.

The U.S. seat on Gavi’s board represents a direct governance role that allows American officials to participate in strategic decisions about vaccine procurement, distribution priorities, and safety protocols. This level of involvement provides the Trump administration with the accountability measures it demanded before releasing the congressionally appropriated funds.

Broader Implications for Global Immunization

Gavi has played a pivotal role in expanding vaccine access to children in developing nations since its founding in 2000. The organization works with governments, international organizations, and pharmaceutical manufacturers to ensure affordable vaccine prices and reliable supply chains. The temporary funding freeze had raised concerns among global health advocates about potential disruptions to immunization campaigns in vulnerable populations.

The restoration of U.S. funding ensures continuity for programs that protect children from diseases including measles, polio, diphtheria, and pneumonia. Gavi’s model combines bulk purchasing power with financial support to help countries strengthen their healthcare infrastructure and achieve higher vaccination coverage rates among their populations.